Hackensack, NJ – November 13, 2019 – Champions Oncology (NASDAQ: CSBR), an end-to-end R&D Oncology solutions company announced today that they have entered into a strategic partnership with PhenoVista Biosciences.
Champions Oncology and PhenoVista Biosciences Announce a Strategic Partnership to provide Oncology Imaging-Based Phenotypic Assays for Preclinical Drug Development
Nov 13, 2019 10:00:00 AM / by Champions Oncology
Champions Oncology Partners with TransCure bioServices to Expand European Business and Operations
May 30, 2019 10:00:00 AM / by Champions Oncology
HACKENSACK, NJ – May 30, 2019 – Champions Oncology, Inc. (NASDAQ: CSBR), engaged in an end-to-end range of research and development technology solutions and services to improve the development and use of oncology drugs, today announced they have partnered with TransCure bioServices to expand the pharmacology operations of Champions’ translational oncology tools throughout Europe.
Champions Oncology Reports Record Quarterly Revenue of $6.2 Million
Sep 13, 2018 10:00:00 AM / by Champions Oncology
Reiterates Expectations for Revenue Growth of at Least 20% for Fiscal Year 2019
Hackensack, NJ – September 13, 2018 – Champions Oncology, Inc. (Nasdaq: CSBR), engaged in an end-to-end range of research and development technology solutions and services to improve the development and use of oncology drugs, today announced its financial results for the first fiscal quarter ended July 31, 2018.
Champions Oncology Granted Full Accreditation by the AAALAC
Aug 8, 2018 8:30:17 AM / by Paul McGarry
Hackensack, NJ – August 8, 2018 – Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced that its new facility in Rockville, MD has been granted Full Accreditation by the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) International. AAALAC commended Champions for the quality and dedication of the staff, the superior quality of the animal facilities, the excellent program of veterinary medical care, and the highly knowledgeable and conscientious Institutional Animal Care and Use Committee.
Champions Oncology Reports Record Annual Revenue Exceeding $20M for Fiscal Year Ended April 30, 2018
Jul 27, 2018 9:53:44 AM / by Paul McGarry
Expects Revenue Growth of at Least 20% for Fiscal Year 2019
Hackensack, NJ – July 26, 2018 – Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced its financial results for the fourth fiscal quarter and 12 months ended April 30, 2018.
Champions Oncology Partners with Puma Biotechnology and NSABP Foundation on Metastatic Breast and Colon Cancer Co-clinical PDX Studies
Jun 18, 2018 5:25:35 PM / by Cindy Lanzendoen
Hackensack, NJ – June 18, 2018 – Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced that they have partnered with NSABP Foundation, Inc. (formerly National Surgical Adjuvant Breast and Bowel Project) and Puma Biotechnology, Inc. (Nasdaq: PBYI) to develop patient derived xenograft (PDX) models in two multi-center co-clinical PDX trials.
Champions Oncology to Present at the 3rd Annual Disruptive Growth & Healthcare Conference on May 9th
May 3, 2018 9:27:54 AM / by Paul McGarry
HACKENSACK, N.J., - May 3, 2018 - Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced that management will be presenting at the 3rd annual Disruptive Growth & Healthcare Conference on Wednesday, May 9th at 8:40am. The conference is being hosted by RHK Capital and ReedSmith LLP, at Reed Smith’s offices located at 599 Lexington Avenue.
Champions Oncology Adds Amy Wesa, Ph.D, as Director of Immuno-Oncology Research
May 1, 2018 9:31:57 AM / by Paul McGarry
Experienced Scientist to Lead Immuno-Oncology Research, Driving Significant Expansion of Market Opportunity
Hackensack, NJ – May 1, 2018 – Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced that Amy Wesa, Ph.D, has joined the company as Director of Immuno-Oncology Research.
Champions Oncology to Present at The MicroCap Conference on April 10th in New York City at the Essex House
Apr 3, 2018 9:34:28 AM / by Paul McGarry
Hackensack, NJ – April 3, 2018 – Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced that management will be presenting at this year’s MicroCap Conference on Tuesday, April 10, 2018 at 9:30am.
Champions Oncology Reports Quarterly Revenue of $5.1 Million
Mar 16, 2018 11:50:20 AM / by Paul McGarry
Company Generates Positive Cash Flow from Operations; Reiterates Expectations for Revenue Growth of at Least 20% for Fiscal Year 2018
Hackensack, NJ – March 15, 2018 – Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced its financial results for the third fiscal quarter and nine months ended January 31, 2018.